artificial digital twin

Artificial integrates NVIDIA’s BioNeMo to advance AI-driven drug discovery workflows

Artificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.

Mike Hampton, Rob Brown

Sapio Sciences bolsters leadership team to accelerate AI-driven lab informatics evolution

Sapio Sciences has announced significant leadership changes designed to strengthen its position in the AI-driven lab informatics sector. The Baltimore-based company, known for its “science-aware” platform, has appointed Mike Hampton as Chief Commercial Officer while simultaneously establishing a dedicated Scientific Office to enhance its research and development capabilities.

BioMerieux logo

Ten-minute cardiac diagnostics: bioMérieux’s strategic acquisition targets emergency care transformation

bioMérieux has announced the acquisition of SpinChip Diagnostics ASA, a privately held Norwegian company specialising in rapid immunoassay diagnostics. The €138 million deal will see bioMérieux acquire 100% ownership of the company, with a cash outlay of approximately €111 million, accounting for the 20% minority stake bioMérieux has held since March 2024.

William J. Kullback

Nuclera enhances its leadership team with the appointment of William J. Kullback as non-executive director

Nuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.

Dr Michael Murray, Dr James Clark, Dr Nel Moore

Glox Therapeutics invigorates leadership team to advance bacteriocin-based antibiotics

Glox Therapeutics has announced strategic appointments to accelerate the development of its novel bacteriocin-based antibiotic platform, with Dr Michael Murray joining as Chair and Dr Nel Moore strengthening the Scientific Advisory Board. The Glasgow-based biotechnology company is pioneering a distinctive approach to combating antimicrobial resistance (AMR) through engineered protein bacteriocins that selectively target drug-resistant pathogens.

Eleva Bauer

Eleva strengthens clinical leadership with appointment of Martin Bauer as CMO

Eleva, the Freiburg-based biopharmaceutical company specialising in difficult-to-produce biologics via its proprietary moss-based expression system, has announced a significant addition to its leadership team as it prepares to enter a crucial clinical development phase.

patient bed heart blood test instr

Impact of glycosylation on NT-proBNP immunoassay performance

by Dr Aleksandra Havelka Assays for NT-proBNP form a key part of diagnosing/ruling out, predicting and managing heart failure. CLI chatted to Dr Aleksandra Havelka (Gentian Diagnostics) to find out more about the challenges and limitations of measuring NT-proBNP concentrations, particularly the effects of glycosylation, and what developments are on the horizon to overcome these […]

AdobeStock 198481611

Laboratory diagnosis of Pneumocystis jirovecii pneumonia

by Dr Osaretin Emmanuel Asowata The detection of Pneumocystis jirovecii in immunocompromised patients is crucial for the treatment of Pneumocystis jirovecii pneumonia (PCP) and to prevent invasive infection. However, PCP can be challenging to diagnose clinically, as symptoms are non-specific. There are several laboratory methods that can be used to diagnose PCP and their advantages […]

Indica Labs

First Swiss public health institute deploys cloud-based digital pathology

University of Bern makes landmark move to AWS-powered HALO AP platform for diagnostic tissue analysis

synexa

Synexa achieves highest My Green Lab certification for sustainable bioanalytical practices

Laboratories are among the most resource-intensive environments in scientific research, consuming vast quantities of energy, water, and disposable materials. However, a growing movement towards sustainable laboratory practices is gaining momentum within the bioanalytical sector, as evidenced by Synexa Life Sciences’ recent achievement.